<DOC>
	<DOCNO>NCT00602342</DOCNO>
	<brief_summary>The objective study bioequivalence Roxane Laboratories ' terbinafine tablet , 250 mg , LamisilÂ® Tablets , 250 mg ( Novartis Pharmaceutical Corporation . ) fast condition use single-dose , randomize , 2-treatment , 2-period , 2-sequence crossover design .</brief_summary>
	<brief_title>Bioequivalency Study Terbinafine Tablets Under Fasting Conditions</brief_title>
	<detailed_description />
	<mesh_term>Onychomycosis</mesh_term>
	<mesh_term>Terbinafine</mesh_term>
	<criteria>No clinically significant abnormal finding physical examination , medical history , clinical laboratory result screen . Positive test HIV , Hepatitis B , Hepatitis C. Treatment know enzyme alter drug . History allergic adverse response terbinafine comparable similar product .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>February 2008</verification_date>
</DOC>